Lucas K. Vitzthum

ORCID: 0000-0003-2033-6874
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Advanced Radiotherapy Techniques
  • Lung Cancer Diagnosis and Treatment
  • Lung Cancer Treatments and Mutations
  • Head and Neck Cancer Studies
  • Medical Imaging Techniques and Applications
  • Radiomics and Machine Learning in Medical Imaging
  • Statistical Methods in Clinical Trials
  • Radiation Therapy and Dosimetry
  • Health Systems, Economic Evaluations, Quality of Life
  • Advanced Causal Inference Techniques
  • Pain Management and Opioid Use
  • Artificial Intelligence in Healthcare
  • Gastric Cancer Management and Outcomes
  • Esophageal Cancer Research and Treatment
  • Opioid Use Disorder Treatment
  • Colorectal and Anal Carcinomas
  • Advances in Oncology and Radiotherapy
  • Lung Cancer Research Studies
  • Colorectal Cancer Surgical Treatments
  • Prostate Cancer Treatment and Research
  • Palliative Care and End-of-Life Issues
  • Pancreatic and Hepatic Oncology Research
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Economic and Financial Impacts of Cancer
  • Management of metastatic bone disease

Stanford University
2020-2025

Stanford Cancer Institute
2021-2024

Stanford Medicine
2020-2023

Cancer Prevention Institute of California
2023

University of California, San Diego
2017-2021

Moores Cancer Center
2021

UC San Diego Health System
2020

Precision for Medicine (United States)
2018-2019

University of Minnesota
2014-2019

NRG Oncology
2018

Background African American (AA) men in the general US population are more than twice as likely to die of prostate cancer (PC) compared with non‐Hispanic white (NHW) men. The authors hypothesized that receiving care through Veterans Affairs (VA) health system, an equal‐access medical would attenuate this disparity. Methods A longitudinal, centralized database >20 million veterans was used assemble a cohort 60,035 (18,201 AA [30.3%] and 41,834 NHW [69.7%]) who were diagnosed PC between...

10.1002/cncr.32666 article EN publisher-specific-oa Cancer 2020-01-27

Defining the loss function is an important part of neural network design and critically determines success deep learning modeling. A significant shortcoming conventional functions that they weight all regions in input image volume equally, despite fact system known to be heterogeneous (i.e., some can achieve high prediction performance more easily than others). Here, we introduce a region-specific lift implicit assumption homogeneous weighting for better learning. We divide entire into...

10.1109/tpami.2023.3289667 article EN IEEE Transactions on Pattern Analysis and Machine Intelligence 2023-06-26

Radiotherapy may cause grade ≥3 cardiac events, necessitating a better understanding of risk factors. The potential predictive role imaging biomarkers with radiotherapy doses for event occurrence has not been studied.

10.1016/j.jaccao.2023.08.007 article EN cc-by JACC CardioOncology 2023-10-04

Using routine preradiation treatment CT simulation scans and tumor segmentation data, a deep learning model was developed to detect segment lung tumors, good performance achieved on diverse datasets.

10.1148/radiol.233029 article EN Radiology 2025-01-01

IntroductionLung cancer survival is improving in the United States. We investigated whether there was a similar trend within Veterans Health Administration (VHA), largest integrated healthcare system States.MethodsData from Affairs Central Cancer Registry (VACCR) were analyzed for temporal trends using Kaplan-Meier (K-M) estimates and linear regression.Results54,922 identified with lung diagnosed 2010-2017. Histologies classified as non-small cell (NSCLC) (64.2%), small (SCLC) (12.9%),...

10.1016/j.cllc.2024.02.009 article EN cc-by Clinical Lung Cancer 2024-03-02

Previous studies have reported conflicting information regarding the prognostic role of p16 in nonoropharyngeal head and neck squamous cell carcinoma (HNSCC). Using US Veterans Affairs database, we analyzed 1448 patients with locoregionally advanced HNSCC known status diagnosed between 2005 2015 treated surgery, radiotherapy, or chemoradiotherapy. Tumor was determined through manual review pathology reports primary tumor specimens. Oropharyngeal (n = 1061) 387; hypopharyngeal, laryngeal,...

10.1093/jnci/djy072 article EN JNCI Journal of the National Cancer Institute 2018-03-22

Abstract Background Although opioids play a critical role in the management of cancer pain, ongoing opioid epidemic has raised concerns regarding their persistent use and abuse. We lack data-driven tools oncology to understand risk adverse opioid-related outcomes. This project seeks identify clinical factors create score help patients at Methods Within cohort 106 732 military veteran survivors diagnosed between 2000 2015, we determined rates posttreatment use, diagnoses abuse or dependence,...

10.1093/jnci/djz200 article EN JNCI Journal of the National Cancer Institute 2019-10-04

Stereotactic ablative radiotherapy (SABR) is used for treating lung tumors but can cause toxic effects, including life-threatening damage to central structures. Retrospective data suggested that small up 10 cm3 in volume be well controlled with a biologically effective dose less than 100 Gy.

10.1001/jamaoncol.2023.3495 article EN JAMA Oncology 2023-09-14

Abstract Background Biology‐guided radiotherapy (BgRT) is a novel delivery technique that utilizes the tumor itself to guide dynamic of treatment dose tumor. The RefleXion X1 system first developed deliver SCINTIX® BgRT. characterized by its split arc design, employing two 90‐degree positron emission tomography (PET) arcs therapeutic radiation beams in real time, currently cleared FDA treat bone and lung tumors. Purpose This study aims comprehensively evaluate capabilities SCINTIX evaluating...

10.1002/mp.17114 article EN Medical Physics 2024-05-04

Abstract We would like to thank Dr Oleribe for their interest in the study, “Predicting Persistent Opioid Use, Abuse, and Toxicity Among Cancer Survivors”. In critical appraisal, author concludes that there is an increased rate of persistent opioid use among Black veterans because proportion with who were was higher than African American on a census bureau report veterans. While we appreciate author’s investigation into potential racial disparities adverse outcomes, do not agree methodology...

10.1093/jnci/djaf020 article EN JNCI Journal of the National Cancer Institute 2025-02-01

Minority race and lower socioeconomic status are associated with rates of opioid prescription undertreatment pain in multiple noncancer healthcare settings. It is not known whether these differences prescribing exist among patients undergoing cancer treatment.

10.1200/op.20.00773 article EN JCO Oncology Practice 2021-02-03

Abstract Purpose: Previous studies indicate that the benefit of therapy depends on patients' risk for cancer recurrence relative to noncancer mortality (ω ratio). We sought test hypothesis patients with head and neck (HNC) a higher ω ratio selectively from intensive therapy. Experimental Design: analyzed 2,688 stage III–IVB HNC undergoing primary radiotherapy (RT) or without systemic three phase III trials (RTOG 9003, RTOG 0129, 0522). used generalized competing event regression stratify...

10.1158/1078-0432.ccr-19-1832 article EN Clinical Cancer Research 2019-08-17

The aim of this study was to apply the Six Sigma methodology and failure mode effect analysis (FMEA) mitigate errors in intensity modulated radiation therapy (IMRT) stereotactic body (SBRT) treatment planning with first clinical installation RefleXion X1.The approach consisted 5 phases: define, measure, analyze, improve, control. analyze phases process mapping an FMEA IMRT SBRT on X1. multidisciplinary team outlined workflow identified ranked modes associated plan check items using American...

10.1016/j.adro.2023.101186 article EN cc-by-nc-nd Advances in Radiation Oncology 2023-01-26

Comorbidity is an independent predictor of mortality and treatment tolerance in head neck cancer should be considered with regard to intensification. Multiple previously validated models can used evaluate comorbidity propensity benefit from intensive treatment, but they have not been directly compared.An online tool was developed calculate the Charlson Index (CCI), Adult Evaluation-27 (ACE-27), Cumulative Illness Rating Scale for Geriatrics (CIRS-G), Geriatric 8 (G8), Cancer Aging Research...

10.1200/cci.18.00082 article EN JCO Clinical Cancer Informatics 2018-10-04

Abstract Purpose: Cancer treatments can paradoxically appear to reduce the risk of noncancer mortality in observational studies, due residual confounding. Here we introduce a method, Bias Reduction through Analysis Competing Events (BRACE), bias presence Experimental Design: BRACE is novel method for adjusting from confounding proportional hazards models. Using standard simulation methods, compared with Cox regression an unmeasured confounder. We examined estimator distributions, bias, mean...

10.1158/1078-0432.ccr-21-2468 article EN Clinical Cancer Research 2022-02-09

Objectives: In this study, we characterise the imaging-mode performance of positron emission tomography (PET) subsystem RefleXion X1 machine using NEMA NU-2 2018 standard. Methods: The consists two symmetrically opposing 900 arcs PET detectors incorporated into architecture a ring-gantry linear accelerator rotating up to 60 RPM. emissions from tumour are detected by and used guide delivery radiation beam. Imaging on was evaluated based sensitivity detectors, spatial resolution, count-loss...

10.1259/bjr.20220387 article EN British Journal of Radiology 2022-11-01

Atrial fibrillation (AF) has been associated with thoracic radiotherapy, but the specific risk irradiating different cardiac substructures remains unknown. This study sought to examine relationship between irradiation of and clinically significant (grade ≥3) AF. We analyzed data from patients who underwent definitive radiotherapy for localized cancers (non-small cell lung, breast, Hodgkin lymphoma, or esophageal) at our institution 2004 2022. The 2-Gy fraction equivalent dose was calculated...

10.1016/j.jaccao.2024.08.007 article EN cc-by-nc-nd JACC CardioOncology 2024-11-05
Coming Soon ...